A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration
Latest Information Update: 14 Oct 2025
At a glance
- Drugs APL 3007 (Primary) ; Pegcetacoplan (Primary)
- Indications Age-related macular degeneration; Dry macular degeneration
- Focus Therapeutic Use
- Sponsors Apellis Pharmaceuticals
Most Recent Events
- 14 Oct 2025 New trial record